Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.
The effectiveness and safety of once-daily versus several-times-daily aminoglycosides were studied in a meta-analysis. MEDLINE for 1988 to 1995 was searched, and additional studies were identified from review articles and references in retrieved articles. Studies selected for meta-analysis were randomized controlled clinical trials in nonneutropenic adult patients comparing the clinical effectiveness or nephrotoxicity or ototoxicity of once-daily with several-times-daily aminoglycosides. Differences between groups were expressed as odds ratios. The results were combined by the procedure of Mantel and Haenszel, and 95% confidence intervals and exact confidence intervals were computed. An odds ratio smaller than 1 would indicate a lesser likelihood of a given endpoint in the once-daily group, and an odds ratio greater than 1 would indicate a greater likelihood. Eighteen studies involving 2317 patients were included in the meta-analysis. Summary odds ratios were 1.47 for effectiveness (95% CI = 1.13-1.94), 0.56 for ototoxicity (95% CI = 0.26-1.16), and 0.60 for nephrotoxicity (95% CI = 0.40-0.86). A meta-analysis showed that treatment with single daily doses of aminoglycosides seems to be more effective, less nephrotoxic, and as ototoxic as multiple doses daily.
Ferriols-Lisart
R
R
Pharmacy Services, Hospital General (HG), Castellón, Spain.
Alós-Almiñana
M
M
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018849:Controlled Clinical Trials as Topic; D004334:Drug Administration Schedule; D004427:Ear Diseases / Q000139:chemically induced; D005839:Gentamicins / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D007674:Kidney Diseases / Q000139:chemically induced; D008875:Middle Aged; D009428:Netilmicin / Q000008:administration & dosage / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009428:Netilmicin; D000583:Amikacin